yes to China and that's why they pay less upfront given correlating impact on the payback period on lower drug pricing.
Paul made a good fist of it with Alan Kolher IMO, other than his explanation on share price performance (ie missed impact of management crying wolf).
Key take always for me:
- Seems they want to include MRI at baseline, 6 & 12 months for labelling and pricing uplift.
- Safety NO change to rental n600. Research from Proctor on Elimron not cause but disease itself. Irrespective the massive oral overdosing by patients over + 7 years is no way a reflection on how we plan to administer.
- 94% response rate from iPPS
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.020(4.76%) |
Mkt cap ! $158.9M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 41.5¢ | 40.0¢ | $104.0K | 256.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 41244 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 7556 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |